








Long-Acting HIV Treatment Pipeline

	Preclinical	Phase I	Phase II/IIb	Phase III	Bridging	Approved
WEEKLY	 GS-5894		 ULO + ISL*  GS-1720 + GS-4182**	 ISL + LEN		 ABT
2-WEEKLY						 IBA
MONTHLY	 TLD	 GS-3107				
2-MONTHLY					 CAB + LEN***	 CAB + RPV
3-MONTHLY		 GS-3242				
4-MONTHLY		 CAB-ULA	 N6LS + CAB			
6-MONTHLY	 DOR	 VH-079	 VH-499  VH-184  LTZ		 CAB + LEN***	 LEN + ARVs

Dosing Modality:

-  Oral
-  Injectable
-  Implant
-  ARV infusion
-  Injectable + oral
-  Antibody infusion
-  Antibody infusion + injectable

Abbreviations/Notes:

ABT: Abuvirtide
 ARVs: Antiretrovirals
 BIC: Bictegravir
 CAB: Cabotegravir
 DOR: Doravirine
 IBA: Ibalizumab
 ISL: Islatravir
 LEN: Lenacapavir
 LTZ: Lenacapavir + teropavimab + zinlirvimab
 RPV: Rilpivirine
 TLD: Tenofovir disoproxil fumarate + lamivudine + dolutegravir
 ULA: Ultra long-acting
 ULO: Ulonivirine

* : Both Phase II and Phase II/III trials are ongoing
 ** : Phase II/III trial (WONDERS-1) is on hold; WONDERS-2 was terminated
 *** : CAB is given every 2 months and LEN is given every 6 months